RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - June 28, 2017) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today announced that the nominees listed in the management proxy circular dated May 19, 2017 (the "Circular") for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 27, 2017. Detailed results of the vote for the election of directors are set out below:

                 

Name of Nominee		  
Votes For		  
% Votes For		  
Votes Withheld		  
% Votes Withheld
Dr. Khalid Islam   9,243,659   99.97%   2,562   0.03%
Mr. Adrian Haigh   9,243,660   99.97%   2,561   0.03%
Mr. Chris A. Rallis   9,243,017   99.97%   3,204   0.03%
Mr. Marco Brughera   9,243,813   99.97%   2,408   0.03%
Mr. Rostislav Raykov   9,243,761   99.97%   2,460   0.03%
                 

Shareholders voted 97.33% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 99.98% in favour of approving the Company's Shareholder Rights Plan, and 99.96% in favour of the compensation paid to the Company's named executive officers.

Fennec Pharmaceuticals Inc.
Rosty Raykov
Chief Executive Officer
(919) 636-5144